Regulatory approvals, medicine status, safety communications and evidence-based drug updates.
CDSCO’s 26 October 2026 listing highlights a WHO alert concerning falsified DEFITELIO (defibrotide) batch 24GC01A identified in India. Practical verification, quarantine and reporting steps for hospital pharmacies.
WHO’s conditional 5 mg zinc recommendation differs from India’s 2025 NHM age-based 10/20 mg regimen. Compare doses, ORS mixing, dehydration assessment and clinical precautions.
Evidence-based naloxone guide: airway and ventilation first, adult/paediatric label-based injection doses, nasal spray instructions, concentration checks, monitoring and recurrent opioid toxicity.
CDSCO listed teneligliptin–bullous pemphigoid as an ADR signal on 21 September 2026. Understand the DPP-4 inhibitor class context, blistering symptoms and safe clinical response.
FDA has approved tucatinib with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction therapy.
FDA is investigating increased allergic and hypersensitivity reactions linked to Yimmugo IGIV lot C795314 and recommends immediate cessation of use of affected stock.
FDA’s Center for Devices and Radiological Health listed four new device classification actions on 5 October 2026, spanning cardiovascular monitoring, focused ultrasound, hereditary cancer testing and toxicology systems.
The FDA has approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary valve designed to be expanded after implantation as a child grows.
FDA’s September 2026 notable approvals list includes Camzyos (mavacamten) as the first drug approved to improve functional capacity and symptoms in children with a rare inherited heart condition.
Complete hydrocortisone sodium succinate injection guide covering adult and paediatric dosing, reconstitution, IV/IM use, monitoring and medication safety.
